Association Between COVID-19 and Mortality in Hip Fracture Surgery in the National COVID Cohort Collaborative (N3C): A Retrospective Cohort Study
dc.contributor.author | Levitt, Eli B. | |
dc.contributor.author | Patch, David A. | |
dc.contributor.author | Mabry, Scott | |
dc.contributor.author | Terrero, Alfredo | |
dc.contributor.author | Jaeger, Byron | |
dc.contributor.author | Haendel, Melissa A. | |
dc.contributor.author | Chute, Christopher G. | |
dc.contributor.author | Quade, Jonathan H. | |
dc.contributor.author | Ponce, Brent | |
dc.contributor.author | Theiss, Steven | |
dc.contributor.author | Spitler, Clay A. | |
dc.contributor.author | Johnson, Joey P. | |
dc.date | 2022-08-11T08:11:03.000 | |
dc.date.accessioned | 2022-08-23T17:30:03Z | |
dc.date.available | 2022-08-23T17:30:03Z | |
dc.date.issued | 2022-01-04 | |
dc.date.submitted | 2022-02-28 | |
dc.identifier.citation | <p>Levitt EB, Patch DA, Mabry S, Terrero A, Jaeger B, Haendel MA, Chute CG, Quade JH, Ponce B, Theiss S, Spitler CA, Johnson JP. Association Between COVID-19 and Mortality in Hip Fracture Surgery in the National COVID Cohort Collaborative (N3C): A Retrospective Cohort Study. J Am Acad Orthop Surg Glob Res Rev. 2022 Jan 4;6(1):e21.00282. doi: 10.5435/JAAOSGlobal-D-21-00282. PMID: 34982060; PMCID: PMC8735795. <a href="https://doi.org/10.5435/JAAOSGlobal-D-21-00282">Link to article on publisher's site</a></p> | |
dc.identifier.issn | 2474-7661 (Linking) | |
dc.identifier.doi | 10.5435/JAAOSGlobal-D-21-00282 | |
dc.identifier.pmid | 34982060 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/50451 | |
dc.description | <p>The UMass Center for Clinical and Translational Science (UMCCTS), UL1TR001453, helped fund this study.</p> | |
dc.description.abstract | BACKGROUND: This study investigated the outcomes of coronavirus disease (COVID-19)-positive patients undergoing hip fracture surgery using a national database. METHODS: This is a retrospective cohort study comparing hip fracture surgery outcomes between COVID-19 positive and negative matched cohorts from 46 sites in the United States. Patients aged 65 and older with hip fracture surgery between March 15 and December 31, 2020, were included. The main outcomes were 30-day all-cause mortality and all-cause mortality. RESULTS: In this national study that included 3303 adults with hip fracture surgery, the 30-day mortality was 14.6% with COVID-19-positive versus 3.8% in COVID-19-negative, a notable difference. The all-cause mortality for hip fracture surgery was 27.0% in the COVID-19-positive group during the study period. DICUSSION: We found higher incidence of all-cause mortality in patients with versus without diagnosis of COVID-19 after undergoing hip fracture surgery. The mortality in hip fracture surgery in this national analysis was lower than other local and regional reports. The medical community can use this information to guide the management of hip fracture patients with a diagnosis of COVID-19. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34982060&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.rights | Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | COVID-19 | |
dc.subject | hip fracture surgery | |
dc.subject | outcomes | |
dc.subject | mortality | |
dc.subject | UMCCTS funding | |
dc.subject | Epidemiology | |
dc.subject | Immunology and Infectious Disease | |
dc.subject | Infectious Disease | |
dc.subject | Orthopedics | |
dc.subject | Pathological Conditions, Signs and Symptoms | |
dc.subject | Surgical Procedures, Operative | |
dc.subject | Translational Medical Research | |
dc.subject | Virus Diseases | |
dc.title | Association Between COVID-19 and Mortality in Hip Fracture Surgery in the National COVID Cohort Collaborative (N3C): A Retrospective Cohort Study | |
dc.type | Journal Article | |
dc.source.journaltitle | Journal of the American Academy of Orthopaedic Surgeons. Global research and reviews | |
dc.source.volume | 6 | |
dc.source.issue | 1 | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1283&context=umccts_pubs&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/umccts_pubs/273 | |
dc.identifier.contextkey | 28283102 | |
refterms.dateFOA | 2022-08-23T17:30:04Z | |
html.description.abstract | <p>BACKGROUND: This study investigated the outcomes of coronavirus disease (COVID-19)-positive patients undergoing hip fracture surgery using a national database.</p> <p>METHODS: This is a retrospective cohort study comparing hip fracture surgery outcomes between COVID-19 positive and negative matched cohorts from 46 sites in the United States. Patients aged 65 and older with hip fracture surgery between March 15 and December 31, 2020, were included. The main outcomes were 30-day all-cause mortality and all-cause mortality.</p> <p>RESULTS: In this national study that included 3303 adults with hip fracture surgery, the 30-day mortality was 14.6% with COVID-19-positive versus 3.8% in COVID-19-negative, a notable difference. The all-cause mortality for hip fracture surgery was 27.0% in the COVID-19-positive group during the study period.</p> <p>DICUSSION: We found higher incidence of all-cause mortality in patients with versus without diagnosis of COVID-19 after undergoing hip fracture surgery. The mortality in hip fracture surgery in this national analysis was lower than other local and regional reports. The medical community can use this information to guide the management of hip fracture patients with a diagnosis of COVID-19.</p> | |
dc.identifier.submissionpath | umccts_pubs/273 | |
dc.contributor.department | UMass Center for Clinical and Translational Science | |
dc.source.pages | e21.00282 |